Kristin J. Richardson, MD

Articles by Kristin J. Richardson, MD

Dr. Richardson on the Use of CDK4/6 Inhibitors in HR+/HER2- Breast Cancer

April 5th 2019

Kristin J. Richardson, MD, hematology/oncology fellow at Rush University Medical Center, discusses the use of CDK4/6 inhibitors in the treatment of patients with hormone receptor (HR)-positive, HER2-negative metastatic breast cancer.

Latest Updated Articles

Dr. Richardson on the Use of CDK4/6 Inhibitors in HR+/HER2- Breast Cancer
April 5th 2019

Kristin J. Richardson, MD

Articles by Kristin J. Richardson, MD

Dr. Richardson on the Use of CDK4/6 Inhibitors in HR+/HER2- Breast Cancer

Latest Updated Articles

Trending on OncLive

FDA Approves Capivasertib Plus Abiraterone and Prednisone for PTEN-Deficient mHSPC

Luspatercept Misses Primary RBC-TI End Point But Shows Clinically Meaningful Improvement for Anemia in Myelofibrosis

MONUMENTAL-3 Data Support Talquetamab Plus Daratumumab ± Pomalidomide as a New SOC in R/R Myeloma

CLL14 Final Analysis Shows Long-Term PFS Gain With Venetoclax/Obinutuzumab in Previously Untreated CLL

FDA Approves Adjuvant Belzutifan Plus Pembrolizumab in ccRCC